Junjiang Sun

Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose

Zhijian Wu, Junjiang Sun, Taiping Zhang et al. · Molecular Therapy · 2007 · 151 citations · Full text

Life Sciences, Biotechnology, Genetics +17

Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application

Paul E. Monahan, Clinton D. Lothrop, Junjiang Sun et al. · Molecular Therapy · 2010 · 119 citations · Full text

Pharmacy, Molecular Medicine, Translational Sciences +13

Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction

Wenwei Shao, Lauriel F. Earley, Zheng Chai et al. · JCI Insight · 2018 · 117 citations · Full text

Life Sciences, Immunology, Molecular Medicine +17

Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial

Paul E. Monahan, Junjiang Sun, Tong Gui et al. · Human Gene Therapy · 2014 · 107 citations · Full text

Medicine, Hematology, Molecular Medicine +13

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Feng Xue, Huiyuan Li, Xia Wu et al. · The Lancet Haematology · 2022 · 79 citations

Life Sciences, Hematology, Pharmacotherapy +12